Fetal Aneuploidy Screening (Change effective as of 10/07/24: Refer to 3003043)
Also known as: FAS
Use
This assay serves as a non-invasive prenatal screening for the most common fetal chromosomal aneuploidies using cell-free DNA sequencing. It is intended to help identify fetuses at risk for trisomy 13, 18, 21, sex chromosome aneuploidies, and triploidy, primarily for singleton pregnancies from 10 weeks gestation. Positive screening results should be followed by diagnostic testing such as amniocentesis or CVS.
Special Instructions
Not provided.
Limitations
This is a screening, not diagnostic, test. Positive findings require confirmatory diagnostic procedures like amniocentesis or CVS. It is validated only for singleton pregnancies, and not recommended for cases of multiple gestation, donor egg, surrogacy without using the patient's own egg, or prior allogeneic bone marrow transplant. Specimen collection and handling must follow ARUP’s NIPT ANEU kit and Blood Cell‑Free DNA BCT Tube requirements.
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
12-14 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
20 mL maternal blood
Minimum Volume
Not provided
Container
Cell‑Free DNA BCT Tube
Collection Instructions
Maternal specimens must be collected in 2 Cell‑Free DNA BCT tubes using NIPT ANEU kit
Storage Instructions
Refrigerated
Causes for Rejection
Ambient or Frozen specimens; mislabeled or unlabeled specimen; less than 50 % draw
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 10 Days |